Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole

被引：0
|
作者：
Aniruddha S. Karve
Janki M. Desai
Nimita Dave
Trisha M. Wise-Draper
Gary A. Gudelsky
Timothy N. Phoenix
Biplab DasGupta
Soma Sengupta
David R. Plas
Pankaj B. Desai
机构：
[1] University of Cincinnati,Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy
[2] University of Cincinnati College of Medicine,Division of Hematology/Oncology
[3] Cincinnati Children’s Hospital,Division of Oncology
[4] University of Cincinnati College of Medicine,Department of Neurology and Rehabilitation Medicine
[5] University of Cincinnati College of Medicine,Department of Cancer Biology
[6] Nimbus Therapeutics,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 90卷
关键词：
Glioblastoma; Temozolomide; Drug-resistance; Aromatase inhibitors; Letrozole; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：345 / 356
页数：11
相关论文
共 50 条
  • [31] A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells
    Bektas, Meryem
    Johnson, Stewart P.
    Poe, William E.
    Bigner, Darell D.
    Friedman, Henry S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 1053 - 1058
  • [32] The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells
    Rahideh, S. T.
    Keramatipour, M.
    Nourbakhsh, M.
    Koohdani, F.
    Hoseini, M.
    Shidfar, F.
    CELLULAR AND MOLECULAR BIOLOGY, 2017, 63 (02) : 9 - 13
  • [33] Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line
    Miyata, Haruo
    Ashizawa, Tadashi
    Iizuka, Akira
    Kondou, Ryota
    Nonomura, Chizu
    Sugino, Takashi
    Urakami, Kenichi
    Asai, Akira
    Hayashi, Nakamasa
    Mitsuya, Koichi
    Nakasu, Yoko
    Yamaguchi, Ken
    Akiyama, Yasuto
    CANCER GENOMICS & PROTEOMICS, 2017, 14 (01) : 83 - 91
  • [34] Reduced estradiol synthesis by letrozole, an aromatase inhibitor, is protective against development of pentylenetetrazole-induced kindling in mice
    Rashid, Davood
    Panda, B. P.
    Vohora, Divya
    NEUROCHEMISTRY INTERNATIONAL, 2015, 90 : 271 - 274
  • [35] Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
    Generali, Daniele
    Bates, Gaynor
    Berruti, Alfredo
    Brizzi, Maria P.
    Campo, Leticia
    Bonardi, Simone
    Bersiga, Alessandra
    Allevi, Giovanni
    Milani, Manuela
    Aguggini, Sergio
    Dogliotti, Luigi
    Banham, Alison H.
    Harris, Adrian L.
    Bottini, Alberto
    Fox, Stephen B.
    CLINICAL CANCER RESEARCH, 2009, 15 (03) : 1046 - 1051
  • [36] P,53 INHIBITOR ENHANCES TEMOZOLOMIDE CYTOTOXIC ACTIVITY AGAINST GBM
    James, C. David
    Dinca, Eduard
    Lu, Kan
    Prados, Michael
    Vandenberg, Scott
    Sarkaria, Jann
    Haas-Kogan, Daphne
    Berger, Mitchel
    Pieper, Russell
    NEURO-ONCOLOGY, 2008, 10 (05) : 796 - 797
  • [37] Effects of aromatase inhibitor (letrozole) on proinflammatory cytokines from cultured endometrial cells of endometriosis patients.
    Chung, D.
    Cho, D.
    Park, K.
    Lee, B.
    FERTILITY AND STERILITY, 2006, 86 : S267 - S268
  • [38] Advanced breast cancer: Prognostic and predictive factors for the aromatase inhibitor Letrozole
    Possinger, K
    Wischnewsky, MB
    Bohm, R
    Chaudri, HA
    ANNALS OF ONCOLOGY, 1998, 9 : 14 - 15
  • [39] MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
    A. Das
    F. C. Henderson
    M. Alshareef
    G. B. F. Porto
    I. Kanginakudru
    L. K. Infinger
    W. A. Vandergrift
    S. M. Lindhorst
    A. K. Varma
    S. J. Patel
    D. Cachia
    Clinical and Translational Oncology, 2021, 23 : 612 - 619
  • [40] MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
    Das, A.
    Henderson, F. C., Jr.
    Alshareef, M.
    Porto, G. B. F.
    Kanginakudru, I.
    Infinger, L. K.
    Vandergrift, W. A., III
    Lindhorst, S. M.
    Varma, A. K.
    Patel, S. J.
    Cachia, D.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (03): : 612 - 619
12345